ClinicalTrials.gg
CompletedNCT01459809RECOMMENDUpdated Jan 21, 2015

Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients

A Phase 3 interventional study of GLIMEPIRIDE and METFORMIN in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 55 sites in 14 countries. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2015-01-21.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
538
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies testing glimepiride in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, 1 of them phase 3. glimepiride · Diabetes Mellitus, Type 2.

Enrollment
9th of 52
538 · median 169
Started
2012
with 3 others
Phase 3
18 of 52
1 open now
Registered
28th of 52
by date
Lead sponsor
9 of 52
Sanofi

Among the 52 studies testing glimepiride in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 4 that started in 2012, is one of 18 in phase 3, and was the 28th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 52 studies testing glimepiride in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About glimepiride

glimepiride: first FDA approval 1995 (AMARYL), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing glimepiride in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

  • To demonstrate the superiority of glimepiride and metformin free combination in comparison to glimepiride or metformin alone in terms of Hb1Ac reduction during a 24-week treatment period in patients with type 2 diabetes mellitus.

Secondary Objectives:

  • To assess the effects of the free combination of glimepiride and metformin in comparison to glimepiride or metformin alone on:
  • Percentage of patients reaching HbA1c \< 7%
  • Percentage of patients reaching HbA1c \< 6.5%
  • Fasting Plasma Glucose (FPG)
  • Safety and tolerability
Read the detailed description

The study duration for each patient is approximately 27 weeks with 3 periods: 2-week screening period followed by 24-week treatment period where patient is assigned to one of the three arms according to randomization, and 3 days follow-up period with a last call phone visit.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type 2 diabetes mellitus, as defined by the World Health Organization (WHO), diagnosed within one year prior to the screening visit
  • Signed , obtained prior to any study procedure

Exclusion criteria

Exclusion criteria

  • Age \< 18 and => 78 years old
  • \< 7.6% or > 9%
  • > 35 kg/m2
  • Diabetes other than type 2 diabetes (e.g.: type 1 diabetes, diabetes secondary to pancreatic disorders, drug or chemical agent intake...)
  • Subjects currently receiving or who have received any hypoglycemic agent within 3 months before screening visit

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
538 participants (actual)

Study arms

  • Experimental
    ARM 1: glimepiride alone

    24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if Fasting Plasma Glucose (FPG) at baseline \< 180 mg/dL (10 mmol/L) taken once in the morning before breakfast. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg, and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and \> 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.

    Drug: GLIMEPIRIDE

  • Experimental
    ARM 2: metformin alone

    24-week treatment period: After randomization, starting dose will be of 500 mg of metformin twice a day during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 2000 mg, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and \> 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.

    Drug: METFORMIN

  • Experimental
    ARM3: Glimepiride/metformin free combination

    24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if FPG at baseline \< 180 mg/dL (10 mmol/L) taken once in the morning and 500 mg of metformin twice a day taken during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg of glimepiride and 2000 mg of metformin, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain values ≤.

    Drug: GLIMEPIRIDE · Drug: METFORMIN

Interventions

  • Pharmaceutical form: oral Route of administration: oral

    Also known as: HOE490

  • Pharmaceutical form: oral Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Time frame: from baseline to week 24

Secondary outcomes

  1. Percentage of patients with HbA1c < 7%

    Time frame: at week 24

  2. Percentage of patients with HbA1c < 6.5 %

    Time frame: at week 24

  3. Change in Fasting Plasma Glucose (FPG)

    Time frame: from baseline week 24

  4. Number of patients reporting adverse events

    Time frame: overt the 24-weeks treatment period

  5. Frequence and incidence of hypoglycemia

    Time frame: over the 24-weeks treatment period

07

Study locations

55 sites
  • Investigational Site Number 01206
    Algeries, Algeria
  • Investigational Site Number 01203
    Oran, 31000, Algeria
  • Investigational Site Number 01205
    Setif, 19000, Algeria
  • Investigational Site Number 17003
    El Espinal, Colombia
  • Investigational Site Number 170001
    Manizales, 170, Colombia
  • Investigational Site Number 81801
    Cairo, Egypt
  • Investigational Site Number 81802
    Cairo, Egypt
  • Investigational Site Number 81803
    Cairo, Egypt
  • Investigational Site Number 32001
    Guatemala, Guatemala
  • Investigational Site Number 32002
    Guatemala, Guatemala
  • Investigational Site Number 32003
    Guatemala, Guatemala
  • Investigational Site Number 32004
    Guatemala, Guatemala
  • Investigational Site Number 356001
    Bangalore, 560043, India
  • Investigational Site Number 356002
    Bangalore, 560052, India
  • Investigational Site Number 356006
    Ernakulam, India
  • Investigational Site Number 356003
    Indore, 452010, India
  • Investigational Site Number 356009
    Lucknow, 226003, India
  • Investigational Site Number 356010
    Mumbai, India
  • Investigational Site Number 356007
    Nashik, 422002, India
  • Investigational Site Number 356008
    Pune, 411007, India
  • Investigational Site Number 356005
    Varanasi, India
  • Investigational Site Number 364001
    Tehran, 1411413137, Iran, Islamic Republic of
  • Investigational Site Number 364002
    Tehran, 1666694516, Iran, Islamic Republic of
  • Investigational Site Number 36403
    Tehran, Iran, Islamic Republic of
  • Investigational Site Number 42201
    Beirut, Lebanon
  • Investigational Site Number 42202
    Beirut, Lebanon
  • Investigational Site Number 42203
    Chouf, Lebanon
  • Investigational Site Number 422004
    Hazmieh, Lebanon
  • Investigational Site Number 484002
    Guadalajara, 44340, Mexico
  • Investigational Site Number 484003
    Guadalajara, 44670, Mexico
  • Investigational Site Number 643003
    Moscow, 119002, Russian Federation
  • Investigational Site Number 643002
    Saratov, 410012, Russian Federation
  • Investigational Site Number 643001
    St.-Petersburg, Russian Federation
  • Investigational Site Number 710-002
    Durban, 4091, South Africa
  • Investigational Site Number 710-001
    Durban, 4092, South Africa
  • Investigational Site Number 78803
    La Marsa, 2070, Tunisia
  • Investigational Site Number 78804
    La Marsa, 2070, Tunisia
  • Investigational Site Number 78805
    Sfax, Tunisia
  • Investigational Site Number 78801
    Tunis, Tunisia
  • Investigational Site Number 78802
    Tunis, Tunisia
  • Investigational Site Number 78806
    Tunis, Tunisia
  • Investigational Site Number 78807
    Tunis, Tunisia
  • Investigational Site Number 792-004
    Adana, Turkey
  • Investigational Site Number 792-003
    Antalya, 07070, Turkey
  • Investigational Site Number 792-001
    Istanbul, 34722, Turkey
  • Investigational Site Number 792-006
    Istanbul, 34890, Turkey
  • Investigational Site Number 792-002
    Kutahya, Turkey
  • Investigational Site Number 792-005
    Sivas, 58140, Turkey
  • Investigational Site Number 804001
    Kyiv, 02175, Ukraine
  • Investigational Site Number 804002
    Kyiv, 04114, Ukraine
  • Investigational Site Number 804003
    Zaporozhye, Ukraine
  • Investigational Site Number 784-001
    Dubai, United Arab Emirates
  • Investigational Site Number 784-002
    Dubai, United Arab Emirates
  • Investigational Site Number 784-003
    Dubai, United Arab Emirates
  • Investigational Site Number 784-004
    Sharjah, 46458, United Arab Emirates
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2011
First posted
Oct 26, 2011
Start
Feb 2012
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Last update
Jan 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01459809
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 26, 2011
Start date
Feb 2012
Primary completion
Jan 2014
Completion
Jan 2014
Last update
Jan 21, 2015

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glimepiride · Metformin

Start the discussion